AgingResearch.NewsJoin free

Rosiglitazone

Intervention

2 papers2 findings

PubChem 77999ChEBI 50122MeSH D000077154

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 2 independent labs in 2 countries
  • Funders: National Center for Advancing Translational Sciences and 4 more
  • Human trial1
  • Animals1

Outcomes

2

Insulin resistance

downin mice1

1 study

  1. Rosiglitazone decreases insulin resistance in mice.

    “These deleterious alterations were normalized by administering rosiglitazone or a key NAD(+) intermediate, nicotinamide mononucleotide (NMN).”

    Animalsadipocyte-specific Nampt knockout mice

    NAMPT-Mediated NAD(+) Biosynthesis in Adipocytes Regulates Adipose Tissue Function and Multi-organ Insulin Sensitivity in Mice

    Cell reports4 Aug 2016

More on Insulin resistance

Body weight

upin humans1

1 study

  1. Rosiglitazone increases body weight in humans (+2.1 kg).

    “Changes in body weight with liraglutide 1.8 mg (-0.2 kg, baseline 83.0 kg), 1.2 mg (+0.3 kg, baseline 80.0 kg) or placebo (-0.1 kg, baseline 81.9 kg) were less than with rosiglitazone (+2.1 kg, P < 0.0001”

    Human trialadded to glimepiride in Type 2 diabetes4 mg/day26 weeksn = 1,041

    Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

    Diabetic medicine : a journal of the British Diabetic Association1 Mar 2009

Latest

Related